Large-scale study shows safety of shorter DAPT therapy with Boston Sci BP stent

Results from a 2000-subject prospective study, EVOLVE Short DAPT, assessing the safety of shorter duration (3 months vs. 12 months or longer) dual antiplatelet therapy (DAPT) in high-bleed risk patients receiving Boston Scientific’s (BSX +0.4%) SYNERGY Bioabsorbable Polymer (BP) stent showed a similar safety profile (non-inferior) to longer-term DAPT. The data were presented at Transcatheter Cardiovascular Therapeutics Conference in San Francisco

The  rate of myocardial infarction (heart attack) in the 3-month DAPT group was 5.6% compared to 5.7% in the 12-month DAPT group. The rate of stent thrombosis (narrowing) favored the 3-month arm, 0.3% versus 1.0%.

Regulatory applications are next up.

The company also announced CE Mark certification for its SYNERGY MEGATRON BP stent.

https://seekingalpha.com/news/3502167-large-scale-study-shows-safety-shorter-dapt-therapy-boston-sci-bp-stent